Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI121
- Development stage
- Preclinical
- Lead developer
- Biom Pharmaceutical
- Modality
- Small Molecules
01
Overview
BI121 is a preclinical small molecule drug candidate developed by Biom Pharmaceuticals for the treatment of COVID-19 and other broad-spectrum RNA virus infections. It is a polyphenolic-rich compound isolated from the medicinal plant *Pelargonium sidoides*. BI121 functions by targeting the SARS-CoV-2 spike protein, which prevents the virus from binding to and entering host cells. Research indicates that BI121 maintains activity against multiple SARS-CoV-2 variants, suggesting potential as a broad-spectrum antiviral agent. The compound is being investigated for its ability to inhibit viral entry and replication across various RNA viruses.
02
Targets
dsRNA (Double-stranded RNA)NSP13 (SARS-CoV-2 helicase)SARS-CoV-2 spike
Beyond the preview
Go deeper on BI121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI121.